Literature DB >> 7809384

Suppression of acute inflammation with liposome associated prostaglandin E1.

R G Rossetti1, K Brathwaite, R B Zurier.   

Abstract

Prostaglandin E1 (PGE1) suppresses leucocyte effector function and reduces inflammation in several animal models of acute and chronic inflammation. A drawback to its use as a therapeutic agent is the relatively high doses needed to suppress inflammation. We present evidence in this report that liposome associated PGE1 (LAP) reduces markedly acute inflammation induced in a subcutaneous air pouch by monosodium urate crystals, and by the polypeptide mediators, interleukin 1-beta (IL-1 beta) and tumor necrosis factor alpha (TNF alpha). A single dose of 12 micrograms/kg LAP given intravenously 2 hr after inflammation was induced, reduced accumulation of cells and exudate by 31-49%.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7809384     DOI: 10.1016/0090-6980(94)90018-3

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  4 in total

1.  The clinical practice guideline for the management of ARDS in Japan.

Authors:  Satoru Hashimoto; Masamitsu Sanui; Moritoki Egi; Shinichiro Ohshimo; Junji Shiotsuka; Ryutaro Seo; Ryoma Tanaka; Yu Tanaka; Yasuhiro Norisue; Yoshiro Hayashi; Eishu Nango
Journal:  J Intensive Care       Date:  2017-07-25

2.  A six week double blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma.

Authors:  W Wasiak; M Szmidt
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

3.  Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA.

Authors:  Michael H Pillinger; Victoria Dinsell; Beth Apsel; Sonia N Tolani; Nada Marjanovic; Edwin S L Chan; Paul Gomez; Robert Clancy; Lih-Fan Chang; Steven B Abramson
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

Review 4.  Beneficial role of bioactive lipids in the pathobiology, prevention, and management of HBV, HCV and alcoholic hepatitis, NAFLD, and liver cirrhosis: A review.

Authors:  Undurti N Das
Journal:  J Adv Res       Date:  2018-12-21       Impact factor: 10.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.